What BeOne Medicines Ltd.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 41 | 204 |
| Total trades | 50 | 282 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 282 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Wang Xiaodong | Director | Nov 09 | Gift · G | −1,183 | — | — | 4,586,930 |
| Ball Titus B. | Principal Accounting Officer | Nov 06 | Open-market sale · S | −26 | $406.34 | −$10.6K | 0 |
| Ball Titus B. | Principal Accounting Officer | Nov 06 | Open-market sale · S | −1,533 | $405.55 | −$622K | 26 |
| Ball Titus B. | Principal Accounting Officer | Nov 06 | Exercise / conversion · M | +679 | $159.03 | +$108K | 1,559 |
| Ball Titus B. | Principal Accounting Officer | Nov 06 | Exercise / conversion · M | +880 | $207.55 | +$183K | 880 |
| Lee Chan Henry | SVP, General Counsel | Nov 05 | Open-market sale · S | −455 | $402.00 | −$183K | 0 |
| Lee Chan Henry | SVP, General Counsel | Nov 05 | Open-market sale · S | −660 | $400.00 | −$264K | 455 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −6,903 | $366.22 | −$2.53M | 0 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −3,965 | $365.43 | −$1.45M | 6,903 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −2,841 | $363.95 | −$1.03M | 10,868 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −8,148 | $363.24 | −$2.96M | 13,709 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −2,331 | $362.35 | −$845K | 21,857 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −320 | $360.64 | −$115K | 24,188 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −1,280 | $359.72 | −$460K | 24,508 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −1,681 | $358.75 | −$603K | 25,788 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −1,239 | $357.54 | −$443K | 27,469 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −1,440 | $355.62 | −$512K | 28,708 |
| Wang Xiaodong | Director | Oct 27 | Open-market sale · S | −880 | $355.56 | −$313K | 30,148 |
| Wang Xiaodong | Director | Oct 27 | Exercise / conversion · M | +31,028 | $36.90 | +$1.14M | 31,028 |
| Wang Xiaodong | Director | Oct 13 | Open-market sale · S | −1,260 | $353.24 | −$445K | 0 |
Loading...